Remidose specializes in two primary product categories: metered dose inhalers and pressurized sublingual sprays. Their metered dose inhalers utilize the same pharmaceutical-grade devices used in the medical industry, providing rapid onset without the adverse effects of smoking or combustible vape cartridges. The pressurized sublingual sprays offer accurate and repeatable experiences with faster onset, better bioavailability, and more pleasant taste compared to manual pump sprays.Current product offerings include Grape, Berry, Strawberry, and Pomegranate Sublingual Oral Sprays (500mg), along with Citrus Live Resin Drops Oil. Their THC oral mists deliver 10mg per spray with 50 sprays per device, while CBD sprays contain 10mg CBD per spray with 75 sprays per device. The company also produces topical products including CBD body sprays with aloe vera and 1:1 THC:CBD topical gels.Remidose has shown strong market performance, particularly in Ohio's Tincture & Sublingual category, climbing from 9th to 8th place with increasing sales through January 2025. Following their partnership with MediPharm Labs, existing customers are now serviced through MediPharm's GMP-certified facilities starting August 2024.
Remidose Aerosols Inc., founded as a federally licensed cannabis processing company located in Stratford, Prince Edward Island, emerged from a vision to revolutionize medical cannabis delivery. Led by CEO Dr. Michael Mayne, who previously served as PEI's Deputy Minister of Health and later as Health PEI's CEO, the company identified a critical gap in the cannabis market: the need for accurate, smoke-free dosing methods.The company gained recognition as a semi-finalist in the BioInnovation Challenge pitch event in 2021, showcasing their innovative approach to cannabis delivery systems. Remidose received support from PEI's Ignition Fund, enabling them to develop and market their groundbreaking inhaler, oral spray, and topical products.In June 2024, Remidose reached a major milestone by entering into a licensing agreement with MediPharm Labs Corp., granting them exclusive global manufacturing, distribution, and sales rights to Remidose's advanced medical cannabis technology. This partnership marked a significant step toward bringing their innovative products to international markets while maintaining their commitment to precision-dosed, pharmaceutical-grade cannabis delivery systems.
Remidose's core mission centers on addressing the huge need for accurate dosing in cannabis consumption. The company is committed to providing consumers access to the therapeutic benefits of cannabis in a smoke-free manner, eliminating the health risks associated with combustion while delivering pharmaceutical-grade precision."We want to make products so you don't get high," explains CEO Michael Mayne, emphasizing their focus on therapeutic benefits over recreational effects. The company aims to shift cannabis consumption away from smoking-focused products, targeting medical users who seek the benefits of cannabis without the stigma or health concerns of traditional consumption methods.Remidose envisions a future where their products are available in pharmacies rather than just cannabis dispensaries, reflecting their commitment to legitimizing medical cannabis through pharmaceutical-grade delivery systems. Their social responsibility extends to making cannabis accessible to patients who need precise, reliable dosing for medical conditions while maintaining the highest safety and quality standards.
At Calm Effect, we're impressed by Remidose's pharmaceutical approach to cannabis delivery. What sets them apart is their use of actual pharmaceutical-industry metered dose devices rather than typical cannabis vaporizers, ensuring each dose is precisely measured and consistent.Their focus on accuracy is remarkable – CEO Michael Mayne identified that most cannabis products lack proper dosing control, leading to unpredictable experiences. Remidose solves this with products delivering exact 10mg doses per spray, allowing users to build up their desired effect gradually.For deal-seekers, Remidose products offer excellent value with 50-75 doses per device, making the cost-per-dose competitive with traditional methods. The rapid onset and better bioavailability mean users need less product to achieve desired effects, stretching their cannabis budget further.We appreciate their medical focus – these aren't just recreational products but legitimate therapeutic delivery systems designed by someone with healthcare administration experience. For consumers seeking precision, discretion, and pharmaceutical-quality standards, Remidose delivers exceptional value.